Compare Cassava Sciences Inc (FLNA) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Weibo Corp — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Weibo Corp trades at $7.86 (market cap $1.91B). The key difference: Weibo Corp is far larger — about 35.9× Cassava Sciences Inc's market cap, and Weibo Corp pays a 7.88% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | WB | |
|---|---|---|
Market Cap | $53.14M | $1.91B |
Sector | Health | Media |
52-Week High | $4.64 | $12.83 |
52-Week Low | $1.09 | $7.20 |
Enterprise Value | -$33.43M | $1.18B |
Dividend Yield | — | 7.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Weibo (WB) trades at $7.875, up 2.81% today, with a bullish technical signal and strong valuation metrics like a P/E of 5.41 and P/B of 0.49. The company reported $449.02M net income for 2025, with a 25.55% margin, and maintains a robust cash position of $2.35B. Recent news highlights its inclusion in value stock lists and AI developments, while earnings have missed expectations in recent quarters.
The outlook is mixed: low valuations and an 8% dividend yield offer upside, but competitive pressures and earnings misses pose risks. Analyst consensus leans buy (45.45%), but sentiment is cautious due to user engagement challenges. Investors should weigh the deep value against structural headwinds in China's social media landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
